Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totaling 177,209 shares, a growth of 469.8% from the May 31st total of 31,099 shares. Based on an average daily trading volume, of 6,889,317 shares, the days-to-cover ratio is currently 0.0 days. Approximately 18.2% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Bluejay Diagnostics Price Performance

Shares of BJDX opened at $3.30 on Friday. The company’s 50-day moving average is $2.80 and its 200-day moving average is $2.69. The firm has a market capitalization of $3.40 million, a PE ratio of -0.28 and a beta of 0.82. Bluejay Diagnostics has a fifty-two week low of $1.62 and a fifty-two week high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. 18.47% of the stock is owned by institutional investors and hedge funds.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.